Maze Therapeutics, Inc. MAZE 深 沪
等待开盘 09-17 09:30:00 美东时间
23.64
+0.390
+1.68%
华盛通- 最 高25.1762
- 今 开22.59
- 成交量 27.25万股
- 最 低 22.59
- 昨 收 23.25
- 总市值 10.37亿
- 52周最高 25.50
- 市盈率 静 303.86
- 换手率 0.62%
- 52周最低 6.71
- 委 比 50.98%
- 总股本 4385.09万
- 历史最高 25.50
- 量 比 0.21
- 振 幅 11.12%
- 历史最低 6.71
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
美股周涨跌榜 | 好莱坞或迎巨震！华纳兄弟探索频道周涨超55%；新思科技绩后暴跌28.9%
好莱坞或迎巨震！华纳兄弟探索频道周涨超55%，传Paramount Skydance拟收购公司；新思科技绩后暴跌28.9%>>
09-13 11:42
美股牛股 | 网红股OpenDoor一夜飙升近80%！公司高管团队调整
网红股OpenDoor一夜飙升近80%！公司高管团队调整；传埃里森家族正筹备收购，华纳兄弟探索频道大涨超29%>>
09-12 14:23
Maze Therapeutics Advances Clinical Programs Amid Financial Stability
Maze Therapeutics, Inc. ( ($MAZE) ) has released its Q2 earnings. Here is a bre...
09-12 11:57
Maze Therapeutics rises on $150M equity offering
Maze Therapeutics (NASDAQ:MAZE) shares rose over 45% premarket on Thursday after the biopharmaceutical company announced an oversubscribed private placement of its securities to raise gross proceeds o...
09-11 19:45
Maze Therapeutics Secures $150M In Oversubscribed Private Placement
Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a
09-11 19:37
Maze Therapeutics Reports Clinical Results From Phase 1 Healthy Volunteer Study Of MZE782, Oral Small Molecule Targeting Solute Transporter, SLC6A19
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKDDose-dependent urinary amino acid excretion
09-11 19:33
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company, announced it has secured approximately $150 million through an oversubscribed private placement of securities. The transaction involved the sale of 4,000,002 shares of common stock at $16.25 per share and 5,231,090 pre-funded warrants at $16.249 each. Key investors include Frazier Life Sciences, Deep Track Capital, and others. Proceeds will fund the advancement of...
09-11 11:35
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Maze Therapeutics announced positive Phase 1 results for MZE782, an oral SLC6A19 inhibitor targeting PKU and CKD. The study demonstrated excellent safety, tolerability, and robust target engagement in healthy volunteers. Dose-dependent increases in urinary phenylalanine (42-fold) and glutamine excretion were observed, supporting PKU treatment potential. A dose-dependent eGFR dip, similar to SGLT2 inhibitors, suggested potential kidney protective ...
09-11 11:30
